{
    "clinical_study": {
        "@rank": "31969", 
        "arm_group": [
            {
                "arm_group_label": "Methyl Aminolevulinate (MAL)", 
                "arm_group_type": "Experimental", 
                "description": "1 gram of Topical Methyl Aminolevulinate (MAL) applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 3 weeks apart)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 gram of placebo cream applied to the whole face 30 minutes before sun exposure for 2 hours (3 sessions , 2 to 3 weeks apart)"
            }
        ], 
        "brief_summary": {
            "textblock": "Treatment of actinic damage has included multiple procedures but to date there is limited\n      scientific evidence to support the preferential use of one of these therapies according to\n      their efficacy, safety and pain tolerance by patients. This study aims to  assess the\n      efficacy of methyl aminolevulinate + daylight vs placebo + daylight to treat facial\n      photodamage"
        }, 
        "brief_title": "Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Facial Photodamage", 
        "condition_browse": {
            "mesh_term": "Facies"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults with symmetric facial photodamage grade 2 or 3 (Dover\u00b4s scale)\n\n          -  Patients willing to participate\n\n          -  Signed informed consent\n\n        Exclusion Criteria:\n\n          -  Pregnant or nursing females\n\n          -  Subjects with any photosensitizing disorder\n\n          -  Any active infectious skin disorder\n\n          -  History of herpes simplex in the face\n\n          -  Subjects with less than 6 months of any previous rejuvenation interfering treatments\n\n          -  History of systemic isotretinoin in the last year\n\n          -  Subjects requiring concurrent treatment that would interfere with study objectives\n             and/or assessments\n\n          -  History of hypersensitivity reactions\n\n          -  Activities with high sun exposure during 48 hours after treatment\n\n          -  Clinical suspicion of any systemic or local malignancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139618", 
            "org_study_id": "2013-01INT"
        }, 
        "intervention": [
            {
                "arm_group_label": "Methyl Aminolevulinate (MAL)", 
                "intervention_name": "Methyl Aminolevulinate (MAL)", 
                "intervention_type": "Drug", 
                "other_name": "Metvix\u00ae"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Vehicle"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Aminolevulinic Acid", 
                "Methyl 5-aminolevulinate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Randomized-controlled-trial", 
            "Methyl-Aminolevulinate", 
            "Daylight", 
            "Photodynamic-therapy"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "sanclementegloria@gmail.com", 
                "last_name": "Dra.Gloria Sanclemente, Dr", 
                "phone": "5743269214"
            }, 
            "contact_backup": {
                "email": "magdaryc@yahoo.com", 
                "last_name": "Magdary Casta\u00f1o, BD", 
                "phone": "574-4447085"
            }, 
            "facility": {
                "address": {
                    "city": "Medellin", 
                    "country": "Colombia", 
                    "state": "Antioquia", 
                    "zip": "01"
                }, 
                "name": "IPS Universitaria"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Colombia"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind Randomized-controlled Trial to Assess the Efficacy of Methyl Aminolevulinate + Daylight vs Placebo + Daylight in Patients With Facial Photodamage", 
        "overall_contact": {
            "email": "sanclementegloria@gmail.com", 
            "last_name": "Gloria Sanclemente, Dr", 
            "phone": "5743217980"
        }, 
        "overall_contact_backup": {
            "email": "magdaryc@yahoo.com", 
            "last_name": "Magdary Casta\u00f1o, BD", 
            "phone": "574-4447085"
        }, 
        "overall_official": {
            "affiliation": "Universidad de Antioquia. Medellin, Colombia", 
            "last_name": "Gloria Sanclemente, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome is global photodamage improvement 1 month after the third daylight PDT session, according to Dover\u00b4s photodamage scale.", 
            "measure": "Global photodamage improvement", 
            "safety_issue": "Yes", 
            "time_frame": "1 month after third session"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139618"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Pain evaluation with the visual analogue scale after 2 hours of sun exposure in each of the sessions performed (Sessions 1, 2  and  3).", 
                "measure": "Pain measurement", 
                "safety_issue": "No", 
                "time_frame": "After 2 hours of sun exposure in each session"
            }, 
            {
                "description": "Specific photodamage severity score for fine lines, coarse lines, tactile roughness, mottled pigmentation, sallowness, and erythema one month after the third daylight PDT session, according to Dover\u00b4s photodamage scale.", 
                "measure": "Specific Photodamage score", 
                "safety_issue": "No", 
                "time_frame": "1 month after the third session"
            }, 
            {
                "description": "Sun irradiation and illuminance quantification during exposure", 
                "measure": "Sun irradiation and illuminance quantification", 
                "safety_issue": "No", 
                "time_frame": "During the 2 hours of each session"
            }, 
            {
                "description": "Any adverse event", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From recruitment until 1 month after the third session"
            }, 
            {
                "description": "Therapy tolerance will be recorded with a  scale that includes a 4-grade severity score for oozing,  erythema, oedema, desquamation, pigmentation,  and vesiculation.", 
                "measure": "Therapy tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "1 week after sessions 1,2 and 3"
            }, 
            {
                "description": "Quality of life assessment (Skindex-29 Instrument)", 
                "measure": "Quality of life assessment (Skindex-29 Instrument)", 
                "safety_issue": "No", 
                "time_frame": "Basal and 1 month after the third session"
            }
        ], 
        "source": "Fundaci\u00f3n Dermabase", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Grupo de Investigacion Dermatologica (GRID)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "IPS Universitaria-Universidad de Antioquia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n Dermabase", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}